Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.https://marketing.lgmpharma.com/LGM-CDMO

    Virtual Booth

    Contact Supplier

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Atezolizumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ORYZON Initiates Phase Ib Study Of Iadademstat In Extensive
    ORYZON Initiates Phase Ib Study Of Iadademstat In Extensive

    09 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/09/3234486/0/en/ORYZON-Announces-First-Patient-Dosed-in-an-Investigator-Initiated-Phase-Ib-Study-of-Iadademstat-in-Extensive-Stage-Small-Cell-Lung-Cancer.html

    GLOBENEWSWIRE
    09 Feb 2026
    Share Share
    FDA Accepts Exelixis' NDA for Zanzalintinib + ICI in Cancer
    FDA Accepts Exelixis' NDA for Zanzalintinib + ICI in Cancer

    02 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260130221586/en/Exelixis-Announces-U.S.-FDA-Accepted-the-New-Drug-Application-for-Zanzalintinib-in-Combination-with-an-Immune-Checkpoint-Inhibitor-for-Patients-with-Metastatic-Colorectal-Cancer

    BUSINESSWIRE
    02 Feb 2026
    Share Share
    Natera Submits Signatera CDx PMA to FDA
    Natera Submits Signatera CDx PMA to FDA

    02 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260129560151/en/Natera-Submits-Signatera-CDx-PMA-to-FDA

    BUSINESSWIRE
    02 Feb 2026
    Share Share
    Oncolytics Biotech Reveals Pelareorep Plus Atezolizumab Efficacy
    Oncolytics Biotech Reveals Pelareorep Plus Atezolizumab Efficacy

    12 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/12/3216966/0/en/Oncolytics-Biotech-Announces-Updated-Clinical-Data-from-GOBLET-Cohort-4-Demonstrating-Activity-of-Pelareorep-Plus-Atezolizumab-in-Third-Line-Anal-Cancer.html

    GLOBENEWSWIRE
    12 Jan 2026
    Share Share
    Chugai's Tecentriq Approved In Japan For Thymic Carcinoma
    Chugai's Tecentriq Approved In Japan For Thymic Carcinoma

    27 Dec 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/drug-approval/chugais-tecentriq-gets-green-light-in-japan-for-hard-to-treat-thymic-carcinoma-18691

    INDPHARMAPOST
    27 Dec 2025
    Share Share
    KaliVir & Roche Partner To Test VET3-TGI With Atezolizumab
    KaliVir & Roche Partner To Test VET3-TGI With Atezolizumab

    19 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251119270996/en/KaliVir-Immunotherapeutics-Announces-Clinical-Trial-Collaboration-and-Supply-Agreement-with-Roche-to-Evaluate-VET3-TGI-in-Combination-with-Atezolizumab-Tecentriq-in-Advanced-Solid-Tumors

    BUSINESSWIRE
    19 Nov 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.